Lilly Post-Prozac Steps Include Charge Related To Ceclor Manufacturing
Executive Summary
Lilly's post-Prozac profit warning includes a charge to eliminate excess manufacturing capacity carried over from the company's last major patent expiration, for the antibiotic Ceclor.
You may also be interested in...
PDI Evista Lessons Learned: Firm Focuses On Smaller Contracts, No Baselines
PDI will focus on smaller contract sales opportunities in the 50-representative range following termination of the Evista promotion deal with Lilly, CEO Charles Saldarini said on a conference call Nov. 12
PDI Evista Lessons Learned: Firm Focuses On Smaller Contracts, No Baselines
PDI will focus on smaller contract sales opportunities in the 50-representative range following termination of the Evista promotion deal with Lilly, CEO Charles Saldarini said on a conference call Nov. 12
Lilly/PDI Chasing 25% Evista Growth: Short In Q1, But Some Positive Signs
Lilly and PDI are aiming at a 25% growth target for Evista (raloxifene) as part of the co-promotion of the osteoporosis drug, PDI CEO Charles Saldarini told investors May 14